Monday, October 29, 2012

• AstraZeneca to Pay Soriot $1.76 Million in Base Salaryat Bloomberg (Mon, Oct 29)

Thursday, October 25, 2012

• Will AstraZeneca Beat These Analyst Estimates?at Motley Fool (Thu, Oct 25)
• Most U.K. Stocks Advance as Economic Growth Tops Forecastat Bloomberg (Thu, Oct 25)
• AstraZeneca Profit Beats Estimates; Forecast Unchangedat Bloomberg (Thu, Oct 25)
• AstraZeneca Confirms P/E of 8at Motley Fool (Thu, Oct 25)
• Should I Buy These 5 Shares?at Motley Fool (Thu, Oct 25)

Wednesday, October 24, 2012

• AstraZeneca Toxic-Cleanup Affiliate Files Bankruptcyat Bloomberg (Wed, Oct 24)

Tuesday, October 23, 2012

• 1 Company Diving off the Patent Cliffat Motley Fool (Tue, Oct 23)
• 10 Shares to Avoid Market Madnessat Motley Fool (Tue, Oct 23)
• AstraZeneca, Ironwood partner on IBS drug in ChinaAP (Tue, Oct 23)

Monday, October 22, 2012

• Lilly Diabetes Medicine Meets Goal in Three Studiesat Bloomberg (Mon, Oct 22)

Friday, October 19, 2012

• 5 Shares for the Week Aheadat Motley Fool (Fri, Oct 19)

Tuesday, October 16, 2012

• Drugs Help Cholesterol Declines in U.S. as Obesity Risesat Bloomberg (Tue, Oct 16)

Monday, October 15, 2012

• Buybacks Tumbling as European CEO Confidence Evaporatesat Bloomberg (Mon, Oct 15)

Sunday, October 14, 2012

• Should I Buy AstraZeneca?at Motley Fool (Sun, Oct 14)
• AstraZeneca Expands R&D in China to Boost Drug Discoveryat Bloomberg (Sun, Oct 14)

Friday, October 12, 2012

• A Big Pharma's Big Delusion?at Motley Fool (Fri, Oct 12)

Thursday, October 11, 2012

• A Quick Look at AstraZeneca's EPS Forecastsat Motley Fool (Thu, Oct 11)

Monday, October 8, 2012

• Targacept announces a new round of job cutsAP (Mon, Oct 8)

Saturday, October 6, 2012

• Pharma’s Diabetes War Escalatesat Motley Fool (Sat, Oct 6)
• This New CEO Hits the Ground Runningat Motley Fool (Sat, Oct 6)

Friday, October 5, 2012

• 1 Deadly Disease Getting Plenty of Attentionat Motley Fool (Fri, Oct 5)
• Novo Says It’s Likely to Benefit From Bristol-Amylin Tie-Upat Bloomberg (Fri, Oct 5)

Thursday, October 4, 2012

• Sanofi Defends Lyxumia Under Scrutiny at Diabetes Meetingat Bloomberg (Thu, Oct 4)

Wednesday, October 3, 2012

• Why Rigel Is Plungingat Motley Fool (Wed, Oct 3)

Add AZN.L News to My Yahoo!